Articles From: Lifshitz & Miller Law Firm Announces Investigation of Endocyte, Inc., Integrys Energy Group, Inc., MICROS Systems, Inc., Measurement Specialties, Inc., and PLX Technology, Inc. to Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation


2014/6/25
NEW YORK , June 25, 2014 /PRNewswire-USNewswire/ -- Endocyte, Inc. Lifshitz & Miller announces that a class action was filed in the United States District Court for the Southern District of Indiana alleging that Endocyte, Inc. ("ECYT") issued false and misleading statements between March 21, 2014 and May 2 , 2014.
Sign-up for Lifshitz & Miller Law Firm Announces Investigation of Endocyte, Inc., Integrys Energy Group, Inc., MICROS Systems, Inc., Measurement Specialties, Inc., and PLX Technology, Inc. investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that data from a Phase 1 study of the selective estrogen receptor modulator (SERM) lasofoxifene were featured in a poster presentation today at ICE/ENDO 2014 in Chicago.
Sign-up for Ligand Announces Presentation of Positive Data from a Phase 1 Study on the Effect of the SERM Lasofoxifene to Increase Testosterone Levels in Men investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it intends to offer, subject to market conditions and other factors, $225 million aggregate principal amount of convertible senior notes due 2019 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and that its Board of Directors has authorized a $200 million share repurchase program over the next 12 months.
Sign-up for Ligand Announces Proposed Offering of $225 Million of Convertible Senior Notes and Announces $200 Million Share Repurchase Program investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that Chairman John W.
Sign-up for Ligand Chairman Dr. John W. Kozarich Named Director of the Year Honoree by Corporate Directors Forum investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced it has expanded its global license agreement with CURx Pharmaceuticals, Inc. to also include the development and commercialization of Ligand’s Captisol-enabled™ Lamotrigine program.
Sign-up for Ligand Licenses Captisol-enabled™ Lamotrigine to CURx Pharmaceuticals, Inc. investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner GlaxoSmithKline (GSK) plc has received approval of a supplemental New Drug Application (sNDA) for the once-daily use of Promacta ® /Revolade ™ (eltrombopag) in patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST). 1 SAA is a blood disorder where the bone marrow fails to make enough red blood cells, white blood cells and platelets.
Sign-up for Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta®/Revolade™ For Use in Patients with Severe Aplastic Anemia investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner GlaxoSmithKline (GSK) plc has announced global revenue for Promacta™/Revolade™ for the second quarter ended June 30, 2014 of $92 million, up 31% from the second quarter of 2013.
Sign-up for Ligand Partner GSK Announces Record Quarterly Promacta™/Revolade™ Revenue of $92 Million investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner GlaxoSmithKline (GSK) plc has started a Phase 3 study to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™) in combination with azacitidine (the current standard of care) versus placebo in combination with azacitidine in intermediate-1, intermediate-2 or high-risk patients with myelodysplastic syndromes (MDS). The global SUPPORT (TRC112121) study will assess the proportion of patients who are platelet transfusion free during the first four cycles of treatment.
Sign-up for Ligand Partner GSK Announces the Start of a Phase 3 Study with Eltrombopag in Patients with Myelodysplastic Syndromes investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner Sage Therapeutics Inc., a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program.
Sign-up for Ligand Partner SAGE Therapeutics Receives Fast Track Designation for Captisol-enabled SAGE-547 to Treat Status Epilepticus investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the August 12, 2014 pricing of $225 million aggregate principal amount of 0.75% convertible senior notes due 2019 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.
Sign-up for Ligand Prices Offering of $225 Million of Convertible Senior Notes investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2014, and provided an operating forecast and program updates.
Sign-up for Ligand Reports Second Quarter 2014 Financial Results investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that total revenues for the second quarter of 2014 are expected to be approximately $10.6 million.
Sign-up for Ligand Reports Second Quarter Revenues and Announces Share Repurchase Program investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced the signing of an exclusive global license agreement with TG Therapeutics, Inc. (NASDAQ: TGTX) for the development and commercialization of Ligand’s Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors.
Sign-up for Ligand Signs Global License Agreement with TG Therapeutics for IRAK-4 Inhibitor Program investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a commercial license agreement with Avion Pharmaceuticals, LLC for the development and commercialization of four Captisol-enabled programs.
Sign-up for Ligand Signs Multi-Program Captisol® License Agreement with Avion Pharmaceuticals investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it will participate in the ROTH Capital Partners’ Healthcare Corporate Access Day to be held on Tuesday, June 24, 2014 in London.
Sign-up for Ligand to Participate in ROTH Capital Partners’ Healthcare Corporate Access Day in London investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G020852-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/8/30/11G020852/Clairvest-64124498660.jpg TORONTO, ON--(Marketwired - August 29, 2014) - Clairvest Group Inc. (TSX: CVG) ("CVG"), together with Clairvest Equity Partners III Limited Partnership ("CEP III", collectively "Clairvest"), announced today that Light Tower Rentals ("LTR") finalized its recapitalization by adding a group of institutional equity investors, following a US$330 million bond offering which was announced on July 21, 2014.
Sign-up for Light Tower Rentals Completes Recapitalization With New Equity Sponsors investment picks
2014/8/5
Live Conference Call and Webcast Scheduled at 11 a.m. ET Wednesday, August 6 at : http://www.media-server.com/m/p/d7zvuusg MCLEAN, Va., Aug.
Sign-up for Lightbridge Announces 2014 Second Quarter Business Update and Financial Results investment picks
MCLEAN, Va., June 18, 2014 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq:LTBR) , a leading innovator of next generation nuclear fuel designs and provider of nuclear energy consulting services to commercial and governmental organizations, today announced that the Company will be added to the Russell Microcap Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indices on June 27.
Sign-up for Lightbridge to be Added to Russell Microcap Index investment picks
2014/7/23
Live Conference Call and Webcast Scheduled at 11 a.m. ET Wednesday, August 6, at : http://www.media-server.com/m/p/d7zvuusg MCLEAN, Va., July 23, 2014 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq:LTBR) , a leading innovator of next generation nuclear fuel designs and provider of nuclear energy consulting services to commercial and governmental organizations, today announced that the conference call and webcast to discuss its 2014 second quarter business update and financial results is scheduled for 11 a.m. ET Wednesday, August 6, 2014.
Sign-up for Lightbridge to Host August 6 Conference Call and Webcast on 2014 Second Quarter Business Update and Financial Results investment picks
MCLEAN, Va., July 9, 2014 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq:LTBR) , a leading innovator of nuclear fuel designs and provider of nuclear energy consulting services, today announced that the Company is a confirmed participant for the U.S. Department of Commerce's 7th Annual U.S. Industry Program in Vienna, Austria, September 21-24, 2014 at the International Atomic Energy Agency General Conference.
Sign-up for Lightbridge to Participate as Member of U.S. Trade Mission to International Atomic Energy Agency Conference in September investment picks
MCLEAN, Va., Sept.
Sign-up for Lightbridge to Present at Euro Pacific Global Investment Conference investment picks
HANOI, Vietnam, Aug.
Sign-up for Lightbridge to Support Vietnam Civil Nuclear Energy investment picks
SANTA CRUZ, Calif.
Sign-up for Lighthouse Bank's Strong Loan Growth Continues in 2nd Quarter 2014 investment picks
BEIJING , June 27, 2014 /PRNewswire/ -- LightInTheBox Holding Co., Ltd.
Sign-up for LightInTheBox Holding Co., Ltd. Raises Second Quarter 2014 Financial Guidance investment picks
Conference Call to be Held at 8:00AM Eastern Time on August 20, 2014 BEIJING , Aug.
Sign-up for LightInTheBox Holding Co., Ltd. Reports Second Quarter 2014 Financial Results investment picks
-- Company continues to focus on growing and strengthening its business operations --
Sign-up for LightInTheBox Settles Class Action Lawsuit investment picks
LONDON , July 23, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has filed an investigational new drug application ("IND") with respect to its naloxone-based opioid overdose reversal nasal spray.
Sign-up for Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse investment picks
LONDON , July 30, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has received a funding commitment from a prominent international research and development foundation.
Sign-up for Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Lifshitz & Miller Law Firm Announces Investigation of Endocyte, Inc., Integrys Energy Group, Inc., MICROS Systems, Inc., Measurement Specialties, Inc., and PLX Technology, Inc. to Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices